Bifogade filer
Invitation to 2cureX Webcast with Q&A on 24 September 2024
Kurs
-0,41%
Likviditet
0,00 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-27 | 15:00 | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-11-14 | - | Extra Bolagsstämma 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-26 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2023-02-10 | - | Extra Bolagsstämma 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-02 | - | Extra Bolagsstämma 2020 |
| 2020-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2019-05-28 | - | Årsstämma |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-02 | - | Extra Bolagsstämma 2019 |
| 2019-03-01 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2018-05-28 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX's Executive Management and Board of Directors are pleased to invite you to a webcast on 24 September 2024 at 20:00 CET.
Live access to the webcast on Tuesday 24, 2024, at 20:00 (CET): Click here to participate
During the webcast, we will discuss 2cureX’s significant developments in the past quarter, including the division of 2cureX into two independent entities: 2cureX AB and 2cureX A/S, each with its own business model. Despite the separation, both companies will work closely together to achieve the shared objective of making Functional Precision Oncology widely accessible to cancer patients worldwide.
The conference call will feature a presentation of 2cureX AB’s new business strategy and will include a live Q&A session with both the Executive Management and the Board of Directors. You are also welcome to submit questions in advance by emailing ir@2curex.com.
A replay of the webcast will be available after the event at www.2curex.com.
We look forward to your participation.
For more information about 2cureX:
Ole Thastrup, CEO
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB